Insider · CIK 0001752827
Daniel C. Martin
Files at DCPH (Deciphera Pharmaceuticals, Inc.). First filing Jan 19, 2023, latest Feb 20, 2024.
In brief
Daniel C. Martin files SEC Form 4 as officer at DCPH (Deciphera Pharmaceuticals, Inc.). Since Jan 19, 2023, Daniel C. Martin has reported 0 open-market buys worth $0 and 8 open-market sells worth $395k, the latest filed on Feb 20, 2024.
A track record needs three past buys with six months of prices behind them; Daniel C. Martin has 0, so none is measured yet.
The newest scored trade: sold $35k of DCPH on Feb 16, 2024, filed Feb 20, 2024, scored 36 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Deciphera Pharmaceuticals, Inc. | $35k 2,267 shares | -4% | - | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | $23k 1,624 shares | -3% | - | |
| 35Weak | Deciphera Pharmaceuticals, Inc. | $27k 1,727 shares | -3% | - | |
| 52Moderate | Deciphera Pharmaceuticals, Inc. | $224k 17,801 shares | -28% | - | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | $17k 1,407 shares | -2% | - | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | $18k 1,238 shares | -2% | - | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | $17k 1,159 shares | -2% | - | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | $34k 1,603 shares | -3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 30, 2023 | Deciphera Pharmaceuticals, Inc. | 17,801 0.02% of outstanding | $224k | Nov 30, 2023 | $17k |
Transactions
Every row this insider has filed, 21 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +20,163 | - | - | 75,281 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -43,951 | - | - | 31,330 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | UTender of shares Common Stock | -31,330 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -62,971 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -54,667 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -44,600 | - | - | 0 | Jun 11, 2024 |
| Jun 11, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -38,900 | - | - | 0 | Jun 11, 2024 |
| Feb 15, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +9,725 | $0.00 | $0 | 57,385 | Feb 20, 2024 |
| Feb 16, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,267 | $15.62 | $35k | 55,118 | Feb 20, 2024 |
| Feb 15, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +38,900 | $0.00 | $0 | 38,900 | Feb 20, 2024 |
| Jan 16, 2024 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,624 | $14.47 | $23k | 47,660 | Jan 18, 2024 |
| Dec 12, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +5,576 | - | - | 51,011 | Dec 14, 2023 |
| Dec 13, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,727 | $15.37 | $27k | 49,284 | Dec 14, 2023 |
| Nov 30, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -17,801 | $12.57 | $224k | 45,435 | Dec 1, 2023 |
| Oct 28, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +5,576 | - | - | 64,291 | Oct 31, 2023 |
| Oct 30, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,407 | $12.02 | $17k | 62,884 | Oct 31, 2023 |
| Jun 16, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,238 | $14.40 | $18k | 58,413 | Jun 21, 2023 |
| Feb 15, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Common Stock | +11,151 | $0.00 | $0 | 59,540 | Feb 17, 2023 |
| Feb 16, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,159 | $15.10 | $17k | 58,381 | Feb 17, 2023 |
| Feb 15, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +44,600 | $0.00 | $0 | 44,600 | Feb 17, 2023 |
| Jan 17, 2023 | DCPH Deciphera Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,603 | $21.24 | $34k | 48,389 | Jan 19, 2023 |
Questions about Daniel C. Martin
Answered from the filings on this page, as of the latest one.
Is Daniel C. Martin buying or selling?
Not in the last 12 months. Daniel C. Martin's latest open-market trade on SEC Form 4 was sold $35k of DCPH on Feb 16, 2024.
How did Daniel C. Martin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel C. Martin has 0.
Where does Daniel C. Martin file Form 4?
Daniel C. Martin has filed Form 4 at DCPH (Deciphera Pharmaceuticals, Inc.) as Chief Commercial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.